ConductScience.org, home

Paper37313232

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.

Berman C and 2 others. touchREV Endocrinol, 2023. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. Papers, record 37313232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37313232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
PubMed
Journal
touchREV Endocrinol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
1.74
iCite
Revised in PubMed
2023-06-15
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Berman CCasey
2Vidmar APAlaina P
3Chao LCLily C

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References78

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120519125GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.Cell Metab2010https://conductscience.org/library/papers/20519125PubMed
224836562The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.Cell Metab2014https://conductscience.org/library/papers/24836562PubMed
329617641Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.Cell Metab2018https://conductscience.org/library/papers/29617641PubMed
427486237Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities.Diabetes Care2016https://conductscience.org/library/papers/27486237PubMed
534964141Clinical review of subcutaneous semaglutide for obesity.J Clin Pharm Ther2022https://conductscience.org/library/papers/34964141PubMed
629941499Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?Diabetes Care2018https://conductscience.org/library/papers/29941499PubMed
734018306Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.Pediatr Diabetes2021https://conductscience.org/library/papers/34018306PubMed
825036533Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.Diabetes Technol Ther2014https://conductscience.org/library/papers/25036533PubMed
931859529Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model.Diabetes Technol Ther2020https://conductscience.org/library/papers/31859529PubMed
1035679098Once-Weekly Exenatide in Youth With Type 2 Diabetes.Diabetes Care2022https://conductscience.org/library/papers/35679098PubMed
119892226Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.Diabetes1999https://conductscience.org/library/papers/9892226PubMed
1233435250Current Perspectives on Management of Type 2 Diabetes in Youth.Children (Basel)2021https://conductscience.org/library/papers/33435250PubMed
1319776173Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.Am J Physiol Renal Physiol2009https://conductscience.org/library/papers/19776173PubMed
1427732328Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.J Clin Endocrinol Metab2017https://conductscience.org/library/papers/27732328PubMed
1511095432Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.J Clin Endocrinol Metab2000https://conductscience.org/library/papers/11095432PubMed
1618201212Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.Diabet Med2008https://conductscience.org/library/papers/18201212PubMed
1736044100GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?Curr Atheroscler Rep2022https://conductscience.org/library/papers/36044100PubMed
1833068776GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.Mol Metab2021https://conductscience.org/library/papers/33068776PubMed
1922369102Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study.Pediatr Diabetes2012https://conductscience.org/library/papers/22369102PubMed
2026394161Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.J Hepatol2016https://conductscience.org/library/papers/26394161PubMed

See all 78 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
41798193Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/41798193PubMed
41300545Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.Children (Basel)2025https://conductscience.org/library/papers/41300545PubMed
41169459Young patients with type 2 diabetes have high relative risks for complications in a country with middle-high sociodemographic index, similarly to those countries with high index.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41169459PubMed
40890660Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication.BMC Public Health2025https://conductscience.org/library/papers/40890660PubMed
40260650Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting.Endocrinol Diabetes Metab2025https://conductscience.org/library/papers/40260650PubMed
39683477Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review.Nutrients2024https://conductscience.org/library/papers/39683477PubMed
39672599Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement.J Clin Endocrinol Metab2025https://conductscience.org/library/papers/39672599PubMed
39493561Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum.World J Diabetes2024https://conductscience.org/library/papers/39493561PubMed
38539310Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).Children (Basel)2024https://conductscience.org/library/papers/38539310PubMed
38173379Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study".Ann Pediatr Endocrinol Metab2023https://conductscience.org/library/papers/38173379PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37313232

GET https://conductscience.org/api/papers/v1/37313232/references?page=2